Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
Looking for a particular Inversago Pharma employee's phone or email?
Inversago Pharma Questions
The Inversago Pharma annual revenue was $405000 in 2026.
Micheline Beauvais is the President and CEO of Inversago Pharma.
7 people are employed at Inversago Pharma.
Inversago Pharma is based in Montreal, Quebec.
The NAICS codes for Inversago Pharma are [3254, 54, 32, 325, 32541, 541].
The SIC codes for Inversago Pharma are [283, 28].
Top Inversago Pharma Employees
-
Micheline Beauvais
President and CEO at Inversago Pharma
Montreal, QC, CA1 -
Jeanmarie Vallet
Acting Chief Business Officer at Inversago Pharma
Brookline, MA, US1 -
Glenn Vraniak
Chief Financial Officer at Inversago Pharma
Bridgewater, New Jersey, United States45+ -
Sabina Bangash
Associate Director at Inversago Pharma
Montreal, QC, CA1
Related Companies
